Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.

about

Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma.Brentuximab vedotin-induced peripheral neuropathy: looking at microtubules.

P2860

Q48098307-656AA519-028C-4267-913B-F28916459EFD Q48274115-8502CD72-B9F3-4111-9532-668ED25D76C8

P2860

Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.

Item

http://www.wikidata.org/entity/Q47251529

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Brentuximab Vedotin for Patien ...... n Analysis of Phase 2 Results.

@en

Brentuximab Vedotin for Patien ...... n Analysis of Phase 2 Results.

@nl

type

Item

label

Brentuximab Vedotin for Patien ...... n Analysis of Phase 2 Results.

@en

Brentuximab Vedotin for Patien ...... n Analysis of Phase 2 Results.

@nl

prefLabel

Brentuximab Vedotin for Patien ...... n Analysis of Phase 2 Results.

@en

Brentuximab Vedotin for Patien ...... n Analysis of Phase 2 Results.

@nl

P1476

Brentuximab Vedotin for Patien ...... n Analysis of Phase 2 Results.

@en

P2093

Auris O Huen

http://www.w3.org/2001/XMLSchema#string

Daniel J Lewis

http://www.w3.org/2001/XMLSchema#string

Madeleine Duvic

http://www.w3.org/2001/XMLSchema#string

Michael T Tetzlaff

http://www.w3.org/2001/XMLSchema#string

Rakhshandra Talpur

http://www.w3.org/2001/XMLSchema#string

P2860

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign--histologically malignant

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.

Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.

Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

CD30+ neoplasms of the skin.

Practical Management of CD30⁺ Lymphoproliferative Disorders.

P304

1302-1306

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMADERMATOL.2017.3593

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

153

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28980004

http://www.w3.org/2001/XMLSchema#string

P932

5817433

http://www.w3.org/2001/XMLSchema#string

Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.

about

P2860

P2860

Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932